Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
47. lappuse
... represented , or promoted for OTC use as an oral wound healing agent is safe and effective for the pur- pose intended must comply with the re- quirements and procedures governing the use of investigational new drugs set forth in part ...
... represented , or promoted for OTC use as an oral wound healing agent is safe and effective for the pur- pose intended must comply with the re- quirements and procedures governing the use of investigational new drugs set forth in part ...
48. lappuse
... represented , or promoted for OTC use to treat or relieve the symptoms or dis- comfort of fever blisters and cold sores is safe and effective for the purpose in- tended must comply with the require- ments and procedures governing the ...
... represented , or promoted for OTC use to treat or relieve the symptoms or dis- comfort of fever blisters and cold sores is safe and effective for the purpose in- tended must comply with the require- ments and procedures governing the ...
49. lappuse
... represented , or promoted for OTC use in the treatment of hypophosphatemia is regarded as a new drug within the meaning of section 201 ( p ) of the Fed- eral Food , Drug , and Cosmetic Act ( the act ) , for which an approved application ...
... represented , or promoted for OTC use in the treatment of hypophosphatemia is regarded as a new drug within the meaning of section 201 ( p ) of the Fed- eral Food , Drug , and Cosmetic Act ( the act ) , for which an approved application ...
50. lappuse
... represented , or promoted for OTC use in the treatment of exocrine pancreatic insufficiency is regarded as a new drug within the meaning of section 201 ( p ) of the Federal Food , Drug , and Cosmetic Act ( the act ) , for which an ...
... represented , or promoted for OTC use in the treatment of exocrine pancreatic insufficiency is regarded as a new drug within the meaning of section 201 ( p ) of the Federal Food , Drug , and Cosmetic Act ( the act ) , for which an ...
60. lappuse
... represented , or promoted for the treatment and / or prevention of noc- turnal leg muscle cramps is regarded as a new drug within the meaning of sec- tion 201 ( p ) of the Federal Food , Drug , and Cosmetic Act ( the act ) , for which ...
... represented , or promoted for the treatment and / or prevention of noc- turnal leg muscle cramps is regarded as a new drug within the meaning of sec- tion 201 ( p ) of the Federal Food , Drug , and Cosmetic Act ( the act ) , for which ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning